Virology > CO-HEP
Copenhagen Hepatitis C Program
Copenhagen Hepatitis C Program (CO-HEP) Copenhagen Hepatitis C Program (CO-HEP) is a joint venture between Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, and Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
CO-HEP currently engages 20 investigators, including senior investigators, postdoctoral fellows, Ph.D. and Masters students, research assistants, and technicians. Research in CO-HEP focuses on basic studies of the hepatitis C virus life cycle with important clinical implications. The aim is to contribute to the development of better therapies and vaccines. Worldwide, over 150 million people are chronically infected with hepatitis C virus, with increased risk of developing liver cirrhosis and cancer, and 500 thousand people die annually from this disease.
CO-HEP was established in 2006 by Professor Jens Bukh. The Program has published front-line basic research on novel hepatitis C virus culture systems and studies of virus neutralization and novel specific antivirals, as well as vaccine related research. Activities have resulted in over 80 publications and several issued patents. Research has in part been supported by public and private research foundations, including the Danish Council for Independent Research, Innovation Fund Denmark, EU, Region Hovedstadens Research Fund for Health Research, Lundbeck Foundation, Novo Nordisk Foundation and the Danish Cancer Society.
In 2014, Professor Jens Bukh was awarded an advanced-top researcher grant from The Danish Council for Independent Research – Sapere Aude for the project entitled “Unravelling the obstacles to culturing hepatitis C virus genotypes 1-7: new opportunities for in vitro studies of antivirals”